Clinical TrialApr 17, 2026, 04:17 PM
Theriva Biologics to Present New VCN-01 Data at AACR Meeting
AI Summary
Theriva Biologics, Inc. announced an upcoming poster presentation of new data and subgroup analyses from its VIRAGE Phase 2b clinical trial. The trial evaluates VCN-01 (zabilugene almadenorepvec) in combination with gemcitabine/nab-paclitaxel for newly-diagnosed metastatic pancreatic cancer patients. The presentation will take place at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, on April 20, 2026.
Key Highlights
- Theriva Biologics to present new data from VIRAGE Phase 2b trial.
- Data on VCN-01 plus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer.
- Presentation at American Association for Cancer Research (AACR) Annual Meeting.
- Poster presentation scheduled for April 20, 2026, 2:00-5:00 PM US PDT.
Price Impact
More from TOVX